Shi Xiaodong, Yu Lijia, Ding Chunguang
National Center for Occupational Safety and Health, National Health Commission of the People's Republic of China, Beijing 102308, China.
Sheng Wu Gong Cheng Xue Bao. 2020 Oct 25;36(10):1979-1991. doi: 10.13345/j.cjb.200355.
Coronavirus disease 2019 (COVID-19) has spread widely on a large scale in the whole world at present, seriously endangering human health. There are still no effective and specific drugs, so it is urgent to find safe and effective therapeutic methods. Mesenchymal stem cells (MSCs) have many biological functions of powerful immunomodulation and tissue repair and regeneration. As a stem cell therapy, it has the potential to reduce the tissue injury and mortality in severe patients infected with novel coronavirus. At present, many research institutions in China and abroad have started a number of clinical research projects about MSCs in the treatment of COVID-19. In addition, those projects have initially confirmed the safety and effectiveness of this therapy. Therefore, this research field has been proved to have a very good clinical therapy prospect.
2019冠状病毒病（COVID-19）目前已在全球范围内大规模广泛传播，严重危害人类健康。目前仍没有有效的特效药物，因此迫切需要找到安全有效的治疗方法。间充质干细胞（MSCs）具有强大的免疫调节以及组织修复和再生等多种生物学功能。作为一种干细胞疗法，其有可能降低新型冠状病毒感染重症患者的组织损伤和死亡率。目前，国内外许多研究机构已启动了多项关于间充质干细胞治疗COVID-19的临床研究项目。此外，这些项目已初步证实了该疗法的安全性和有效性。因此，这一研究领域已被证明具有非常良好的临床治疗前景。
